AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China

AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China

Source: 
Yahoo/Zacks.com
snippet: 

AstraZeneca PLC AZN announced that its partner FibroGen China has received the second marketing approval for roxadustat in China. This time, the Chinese regulatory authority has granted a nod to roxadustat for the treatment of anaemia caused by chronic kidney disease (CKD) in non-dialysis-dependent (NDD) patients.